Motion sickness drugs prevent symptoms. No trial has tested treating them once they start

The two motion sickness drugs with the best evidence — scopolamine (hyoscine) and first-generation antihistamines such as cinnarizine and dimenhydrinate — both prevent symptoms better than placebo, according to Cochrane systematic reviews [s1] [s2]. But both reviews independently reached the same striking conclusion: not a single randomised trial has ever tested whether these drugs relieve motion sickness once the nausea has already begun [s1] [s2]. The evidence is entirely about prevention taken in advance, which is a narrower claim than the way these remedies are usually sold.

What the evidence covers, and what it doesn't

Motion sickness is the cluster of symptoms — nausea, vomiting, pallor, cold sweats, excess saliva, headache — that arises when the perception of motion conflicts with the organs of balance [s1]. The remedies for it span drugs, behavioural techniques, and complementary therapies, but the two best-studied drug classes are the ones examined here [s1].

The scopolamine review, first published in 2004 and updated through 2011, pooled 14 randomised trials enrolling 1,025 subjects, using patches, tablets, oral solutions, or intravenous doses [s1]. Scopolamine was more effective than placebo at preventing symptoms — the core positive finding [s1]. Comparisons against other agents were sparse: it appeared superior to methscopolamine and roughly equivalent to antihistamines, while comparisons with the calcium-channel blocker cinnarizine or with scopolamine-plus-ephedrine combinations were equivocal or minimal [s1]. On side effects, scopolamine was no more likely than other agents to cause drowsiness, blurred vision, or dizziness, though dry mouth was more common with it than with methscopolamine or cinnarizine [s1].

The antihistamine review, published in 2022, included nine randomised trials with 658 participants [s2]. Under real travel conditions, antihistamines were probably more effective than placebo at preventing symptoms: 40% of people on antihistamines were kept symptom-free versus 25% on placebo, a risk ratio of 1.81 (95% confidence interval 1.23 to 2.66), which the reviewers graded moderate-certainty [s2]. The naturally occurring conditions were the ones that produced the clearest signal; results from experimental setups such as rotating chairs were much more uncertain [s2].

The trade-off, quantified

The cost of the antihistamines is sedation, and the review put a number on it. Compared with placebo, antihistamines were more likely to cause sedation — 66% versus 44%, a risk ratio of 1.51 (95% CI 1.12 to 2.02) — while making little or no difference to blurred vision or to measured cognition [s2]. That is the practical bargain of a first-generation antihistamine: a meaningful drop in the odds of feeling sick, bought with a substantial rise in the odds of feeling drowsy. When the two drug classes were compared head to head, the evidence was too uncertain to separate them: scopolamine kept 81% symptom-free versus 71% for antihistamines, but the confidence interval spanned no difference [s2].

The gap both reviews found

The most useful thing these two reviews share is a negative finding. The scopolamine review states that it identified no randomised controlled trials examining the effectiveness of scopolamine in treating established symptoms of motion sickness [s1]. The antihistamine review reports exactly the same void: no studies reported results on the resolution of existing motion sickness symptoms [s2]. Both also note thin-to-absent evidence in children — the antihistamine trials had an age range starting at 16, and neither review could speak to paediatric use with confidence [s2].

This is why the honest framing is prevention, not cure. The trials enrolled susceptible people and dosed them before exposure; nobody has run the experiment of giving the drug to someone already green and measuring whether they recover faster. It may well help — the pharmacology is the same — but that is inference, not evidence, and the distinction is the whole point of reading the reviews rather than the packaging.

What holds up

For a traveller prone to motion sickness, the defensible summary is that scopolamine and first-generation antihistamines have real, if modest, preventive evidence behind them, taken ahead of travel, with sedation the main trade-off for the antihistamines [s1] [s2]. What has no trial evidence is treating an episode in progress, and what has little is use in children [s1] [s2]. Which agent, which route, and whether any of them suits a given person — especially children, older travellers, or anyone on other medications — are clinical questions this article does not answer.